Tiers name what a vendor publishes, not a verdict on any product's purity or quality.
Lab-verifiable COAs: certificates that open on the testing lab's own site (the seal's ring shows what share of them do).
Third-party COAs: certificates attributed to a third-party lab, which may be hosted only on the vendor's site.
Tiers follow the Vendor Score (90+ and 80–89), which is 87% COA evidence; the numeral in each seal is that score.
Affiliate relationships never affect tiers, selection or order. How the Vendor Score works
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide and melanocortin receptor agonist derived from the peptide Melanotan II, studied in laboratory and preclinical models for its activity at melanocortin receptors such as MC3R and MC4R. It is supplied as a research-use-only material and is not intended for human or veterinary use. This index tracks per-milligram pricing for PT-141 across research-chemical (RUO) vendors so researchers can compare current listings.
Evidence brief
PT-141 (bremelanotide) is a melanocortin-receptor agonist approved by the US FDA and studied in two phase 3 randomized controlled trials for hypoactive sexual desire disorder in premenopausal women.
Compare by exact vialThe small sealed glass container a compound ships in.The small sealed glass container a compound ships in. size:
5mg (3 vendors)10mg (65 vendors)
FDA-approved as bremelanotide (Vyleesi) for hypoactive sexual desire disorder in premenopausal women; not approved in the EU or UK.Research use only — not medical advice.
Size, form & budget
Price includes the displayed code where available. Shipping and tax are extra. Unknown sizes or prices are excluded when those filters are set.
Your comparison
Selections stay on this browser. Prices and stock come from the current page; review freshness and COA notes for each offer. Scroll sideways to see every offer.
Select up to four offers to compare side by side. Click a column heading to sort. Click again to reverse. Scroll sideways for more columns.
Tick up to four offers to compare side by side. Use Sort by to reorder. COA counts are each vendor's own library; batch match is not assumed.
PT-141 · all tracked vendors · all tracked peptide listings, including out-of-stock products. Prices and stock reflect the last check. Non-comparable products do not enter market rankings. Trust scores measure published evidence, not product safety.
PT-141 (bremelanotide) is a melanocortin-receptor agonist approved by the US FDA and studied in two phase 3 randomized controlled trials for hypoactive sexual desire disorder in premenopausal women.
Source-linked reference figures with the population and study context alongside each amount. Study arms are not a starting dose, titration schedule, or personal treatment plan. Label records refer to the named approved medicine, not vendor products.
FDA-approved label dose
1.75 mg as a single dose, as needed
human · premenopausal women with hypoactive sexual desire disorder · FDA label (Vyleesi) · Route reported: subcutaneous
Dose administered in a two phase 3 randomised double-blind trials (RECONNECT) (human, premenopausal women with hypoactive sexual desire disorder)
1.75 mg as needed
human · premenopausal women with hypoactive sexual desire disorder · two phase 3 randomised double-blind trials (RECONNECT) · Route reported: subcutaneous
Research use only — this reports what an FDA label or a peer-reviewed study published, tied to its species and study context. It is not medical advice, not a recommendation to use, and no dose here is generated by pepmg. Any dosing decision is for a qualified professional. Animal-study amounts do not establish a human dose.
Reconstitution calculator → · Converts your entered quantities; it does not select a dose or establish suitability for use.
Bremelanotide (Vyleesi™) is a melanocortin receptor agonist recently approved in the USA for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire…
Systematic reviewhumanThe Annals of pharmacotherapy · 2020 · PMID 31893927
Objective: To review data regarding bremelanotide, a recently approved therapy for hypoactive sexual desire disorder (HSDD). Data Sources: Literature search of Medline, SCOPUS, and EMBASE was performed using the search terms bremelanotide,…
Reviewspecies not classifiedNeurology international · 2022 · PMID 35076581
Hypoactive sexual desire disorder (HSDD) is a persistent deficiency or absence of sexual fantasies and desire resulting in significant distress or interpersonal difficulty. Women with this disorder may display a lack of motivation for…
A few representative studies, each summarized on this site with the PubMed record linked beside it — not an endorsement or a claim that any result applies to human use. Read them and judge for yourself. Everything here is research use only.
Per-mg prices vary because vendors sell PT-141 in different vial sizes, synthesis batches, and stated purity grades, and because packaging, lyophilization, and shipping overhead get distributed differently across small versus bulk quantities. Comparing normalized $/mg alongside a current COA lets a researcher weigh cost against documented identity and purity rather than headline vial price alone.
▸ Reading the COA
For PT-141, confirm identity by mass spectrometry against the expected monoisotopic mass (roughly 1024–1025 Da for the free peptide, molecular formula C50H68N14O10) and verify HPLC purity is reported, with many research buyers treating >=98% as a reasonable threshold. Check that the COA is lot-matched to the vial you receive and dated. Common flags on a melanocortin peptide like this include truncated or deletion sequences and acetate/TFA counter-ion content, so scan for reported related-substance peaks and residual-solvent notes rather than accepting a purity number in isolation.
▸ FAQ
What storage conditions do vendors typically state for lyophilized PT-141 as a research material?
As a lyophilized (freeze-dried) powder, PT-141 is generally described as most stable when kept cold and dry, and vendors commonly specify storage at -20C protected from light and moisture. This is general storage information for the research material and is not use or handling guidance. Always defer to the specific storage conditions and stability window printed on the vendor's COA or product page.
What is a COA and what should I check for on one for PT-141?
A COA (Certificate of Analysis) is the batch-specific document a vendor issues to characterize a given lot of material. For PT-141, check that it identifies the peptide by mass spectrometry against the expected mass, reports HPLC purity with a chromatogram, lists the lot number, and matches the vial you received. It documents identity and purity of the compound; it is not a statement about any outcome or suitability for use.
Why do per-mg prices for PT-141 differ so much between vendors?
Differences usually trace to vial size (bulk lots lower the $/mg), the synthesis batch and stated purity grade, and how fixed costs like peptide synthesis, lyophilization, QC testing, and cold shipping are amortized across the quantity sold. Two listings can also differ because one includes a current lot-matched COA and third-party verification while another does not, which affects the effective value of the material.
All products listed are sold by third-party vendors for laboratory and research use only (RUO). Where an FDA label or a peer-reviewed study has published a dose, pepmg reports it with the source named, because that is safer than guessing. It is a report, not medical advice and not a recommendation to use anything. pepmg sells nothing and ships nothing. Listings are price-tracking data, not endorsements.
✓
+ Get the free Weekly Price Index One email a week — where every compound's $/mg moved. No spam.